Product logins

Find logins to all Clarivate products below.


Transcatheter Embolization and Occlusion Devices | Market Insights | Asia Pacific | 2024

The Asia Pacific TEO device market will see moderate growth through 2032 driven by the launch and increasing adoption of new devices backed by favorable clinical data, increasing access to the TEO devices, and rising demand for TEO procedures among the expanding patient population due to the faster recovery and better cost-effectiveness associated with these minimally invasive devices. However, the ongoing cost constraints in the region will remain a challenge for this market.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO devices in Asia Pacific from 2019 through 2032.

Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific
The Asia Pacific CRM device market will register modest growth over the forecast period. Key growth drivers include the rising adoption of premium-priced technologies such as CRT devices, leadless…
Report
Aortic Repair Devices – Market Insights – Asia Pacific
The Asia Pacific aortic repair device market is projected to experience robust growth during the forecast period, fueled by rising endovascular procedure volumes, ongoing innovation in aortic stent…
Report
Cardiac Rhythm Management Devices | Market Insights | Asia Pacific (Supplemental) | 2025
The Asia Pacific CRM device market will experience modest growth over the forecast period, driven primarily by the increasing volume of ICM procedures and the adoption of premium-priced devices,…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…
Report
Structural Heart Closure Devices – Market Insights – Asia Pacific
The Asia Pacific structural heart closure device market will grow strongly overall through 2034, supported by rising AF prevalence, increasing physician confidence in structural heart interventions…